Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) have received an average recommendation of “Moderate Buy” from the ten brokerages that are presently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $29.2857.

A number of equities analysts have issued reports on ZVRA shares. Maxim Group lifted their price objective on shares of Zevra Therapeutics from $25.00 to $35.00 and gave the stock a “buy” rating in a report on Wednesday. HC Wainwright reaffirmed a “buy” rating on shares of Zevra Therapeutics in a report on Tuesday. Cantor Fitzgerald lifted their price objective on shares of Zevra Therapeutics from $24.00 to $34.00 and gave the stock an “overweight” rating in a report on Monday. Weiss Ratings downgraded shares of Zevra Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a report on Friday, May 22nd. Finally, Citigroup reissued an “outperform” rating on shares of Zevra Therapeutics in a report on Tuesday.

Zevra Therapeutics Price Performance

ZVRA opened at $12.97 on Friday. The company has a market capitalization of $766.79 million, a price-to-earnings ratio of 6.52 and a beta of 0.91. The firm’s fifty day moving average price is $10.63 and its two-hundred day moving average price is $9.48. Zevra Therapeutics has a 1 year low of $7.16 and a 1 year high of $14.27.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.18 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.12. The firm had revenue of $36.22 million for the quarter, compared to the consensus estimate of $31.96 million. Zevra Therapeutics had a net margin of 101.58% and a return on equity of 51.49%. As a group, equities analysts anticipate that Zevra Therapeutics will post 0.56 EPS for the current year.

Hedge Funds Weigh In On Zevra Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in ZVRA. AIGH Capital Management LLC purchased a new position in shares of Zevra Therapeutics in the 1st quarter worth about $11,184,000. Marshall Wace LLP purchased a new position in shares of Zevra Therapeutics in the 3rd quarter worth about $8,676,000. Rubric Capital Management LP boosted its holdings in shares of Zevra Therapeutics by 60.8% in the 2nd quarter. Rubric Capital Management LP now owns 1,958,318 shares of the company’s stock worth $17,253,000 after buying an additional 740,584 shares during the last quarter. Royce & Associates LP purchased a new position in shares of Zevra Therapeutics in the 3rd quarter worth about $6,574,000. Finally, Adage Capital Partners GP L.L.C. boosted its holdings in shares of Zevra Therapeutics by 15.2% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 4,168,000 shares of the company’s stock worth $36,720,000 after buying an additional 550,000 shares during the last quarter. 35.03% of the stock is owned by hedge funds and other institutional investors.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.